Jim Simons Atea Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,123,400 shares of AVIR stock, worth $4.12 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,123,400

Previous 1,496,303 24.92%

Holding current value

$4.12 Million

Previous $4.56 Million 0.55%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.09 - $4.56 $1.15 Million - $1.7 Million	-372,903 Reduced 24.92%	1,123,400 $4.54 Million
Q4 2023 Feb 13, 2024	BUY	$2.8 - $3.35 $396,933 - $474,902	141,762 Added 10.47%	1,496,303 $4.56 Million
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $26,523 - $33,507	-8,841 Reduced 0.65%	1,354,541 $4.06 Million
Q2 2023 Aug 11, 2023	BUY	$3.21 - $5.06 $2.04 Million - $3.22 Million	635,682 Added 87.35%	1,363,382 $5.1 Million
Q1 2023 May 12, 2023	BUY	$3.0 - $4.97 $321,300 - $532,287	107,100 Added 17.26%	727,700 $2.44 Million

Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.17 $100,919 - $143,144	23,200 Added 3.88%	620,600 $2.99 Million
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $360,144 - $576,624	-65,600 Reduced 9.89%	597,400 $3.4 Million
Q2 2022 Aug 12, 2022	SELL	$5.33 - $8.18 $2.68 Million - $4.11 Million	-502,000 Reduced 43.09%	663,000 $4.71 Million
Q1 2022 May 13, 2022	BUY	$5.5 - $9.19 $2.99 Million - $5 Million	544,200 Added 87.66%	1,165,000 $8.41 Million
Q4 2021 Feb 11, 2022	BUY	$7.67 - $44.59 $4.59 Million - $26.7 Million	598,200 Added 2646.9%	620,800 $5.55 Million
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $482,057 - $792,356	22,600 New	22,600 $792,000

Others Institutions Holding AVIR

# of Institutions

119

Shares Held

49.6M

Call Options Held

108K

Put Options Held

327K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $306M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account